Wednesday, March 13, 2024
Beckman Coulter Diagnostics and Fujirebio have expanded their partnership to focus on developing tests for neurodegenerative diseases. This collaboration aims to refine assays targeting novel biomarkers, particularly those relevant to recently approved monoclonal antibody-based treatments for Alzheimer's disease.
The partnership will specifically focus on enhancing assays like the pTau217 plasma assay by Beckman Coulter and the amyloid beta 1-42 plasma assay by Fujirebio. These assays are intended for integration with Beckman Coulter's DxI 9000 Immunoassay Analyzer, known for its highly sensitive and clinically relevant assays facilitated by the Lumi-Phos PRO substrate.
Fujirebio's expertise in neurological kits and extensive menu of biomarkers will be pivotal in this collaboration. The company has already developed a comprehensive line of research-use blood neurodegenerative biomarkers, including β-amyloid1-42, β-amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, Pan-ApoE, and phospho-Tau217.
By combining Beckman Coulter's innovative technology with Fujirebio's biomarker expertise, the partnership aims to address the challenges of developing highly sensitive assays capable of detecting low concentrations of neurodegenerative disease biomarkers in blood. This collaboration holds promise for advancing the diagnosis, monitoring, and treatment of neurodegenerative diseases, ultimately benefiting patients.
Source: businesswire.com
